Article

Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome

Morehouse School of Medicine, Atlanta (E.O.O.)
New England Journal of Medicine (Impact Factor: 54.42). 11/2012; 367(24). DOI: 10.1056/NEJMoa1210357
Source: PubMed

ABSTRACT Background Ultrafiltration is an alternative strategy to diuretic therapy for the treatment of patients with acute decompensated heart failure. Little is known about the efficacy and safety of ultrafiltration in patients with acute decompensated heart failure complicated by persistent congestion and worsened renal function. Methods We randomly assigned a total of 188 patients with acute decompensated heart failure, worsened renal function, and persistent congestion to a strategy of stepped pharmacologic therapy (94 patients) or ultrafiltration (94 patients). The primary end point was the bivariate change from baseline in the serum creatinine level and body weight, as assessed 96 hours after random assignment. Patients were followed for 60 days. Results Ultrafiltration was inferior to pharmacologic therapy with respect to the bivariate end point of the change in the serum creatinine level and body weight 96 hours after enrollment (P=0.003), owing primarily to an increase in the creatinine level in the ultrafiltration group. At 96 hours, the mean change in the creatinine level was -0.04±0.53 mg per deciliter (-3.5±46.9 μmol per liter) in the pharmacologic-therapy group, as compared with +0.23±0.70 mg per deciliter (20.3±61.9 μmol per liter) in the ultrafiltration group (P=0.003). There was no significant difference in weight loss 96 hours after enrollment between patients in the pharmacologic-therapy group and those in the ultrafiltration group (a loss of 5.5±5.1 kg [12.1±11.3 lb] and 5.7±3.9 kg [12.6±8.5 lb], respectively; P=0.58). A higher percentage of patients in the ultrafiltration group than in the pharmacologic-therapy group had a serious adverse event (72% vs. 57%, P=0.03). Conclusions In a randomized trial involving patients hospitalized for acute decompensated heart failure, worsened renal function, and persistent congestion, the use of a stepped pharmacologic-therapy algorithm was superior to a strategy of ultrafiltration for the preservation of renal function at 96 hours, with a similar amount of weight loss with the two approaches. Ultrafiltration was associated with a higher rate of adverse events. (Funded by the National Heart, Lung, and Blood Institute; ClinicalTrials.gov number, NCT00608491 .).

Download full-text

Full-text

Available from: Eric J Velazquez, Apr 01, 2014
2 Followers
 · 
236 Views
  • Source
    • "These individuals are at high risk for future cardiovascular (CV) events and the presence of other well-established CV risk factors further increases their risk [1]. Muscle strength has been identified as an index of future CV risk and mortality [2] [3] [4] [5]. Studies of the relationship between strength and CV outcomes have mainly been done in non-Hispanic Caucasians from highincome countries [6] and little data are available regarding this relationship in a wider, more heterogeneous sample of people with dysglycemia. "
    International journal of cardiology 04/2014; 174(2). DOI:10.1016/j.ijcard.2014.04.015 · 6.18 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The year 2012 has been extremely interesting concerning new findings on diagnosis, management and therapy of dyslipidaemia, hypertension and kidney disease. Looking at recent lipid disorders studies, two issues have seemed to be especially important-searching for new potent biomarkers of lipid disorders (including studies on dysfunctional High Density Lipoprotein [HDL] cholesterol, as well as subfractions/subpopulations of HDL/Low Density Lipoprotein [LDL] cholesterol) and research on new lipid disorders drugs, especially concerning proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, which seem to be very potent in LDL-C lowering. Within the past year, there has been also growing clinical and research progress in hypertension management, especially concerning Resistant Hypertension (RH). In 2012, many important studies on Renal denervation (RDN), as a method of RH therapy have been published, including the ones with patients with different concomitant diseases (e.g., Chronic Kidney Disease (CKD)), as well as with longer follow-up. On the basis of the available data RDN has gained an important role in RH treatment and has recently been introduced to clinical practice. November 2012 has been critical for new nephrology data, as the most important trails were presented during American Society of Nephrology (ASN) Congress in San Diego. They concerned among others, the problems of secondary hyperparathyroidism management in CKD patients, new data on transplantations (e.g., glucocorticoid avoidance strategy), nephro cardiology (stepped pharmacotherapy algorithm vs. ultrafiltration in heart failure patients with CKD), as well as acute kidney injury and diabetic nephropathy (new data on bardoxolone methyl).
    International Journal of Pharmacology 08/2012; 8(8):659-678. DOI:10.3923/ijp.2012.659.678 · 0.98 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Heart failure (HF) remains a major medical problem, and the European Journal of Heart Failure is dedicated to publishing research further investigating its pathophysiology and diagnosis in order to help clinicians alleviate symptoms and improve patient outcomes.( 1) This review reports on important studies in the field of HF published in 2011. All research areas are addressed, including experimental studies, biomarkers, clinical trials, arrhythmias, and new insights into the role of device therapy.
    European Journal of Heart Failure 08/2012; 14(10):1090-6. DOI:10.1093/eurjhf/hfs121 · 6.58 Impact Factor